Written & medically reviewed by Dr. Jignesh Gala, Vitreoretinal & Cataract Surgeon, Founder & Director — Crystal Clear Eye Clinic and Topax Eye Hospital, Mumbai. Prices last verified: 22 July 2026.

Anti-VEGF Injection Cost in Mumbai (2026) — Every Drug, Every Price, Explained Honestly by a Retina Specialist

⚡ Quick answer: In Mumbai, an anti-VEGF eye injection costs ₹7,000 to ₹65,000 per injection depending on the drug — Avastin and biosimilars (₹7,000–15,000) at the budget end, Accentrix/Eylea (₹18,000–40,000) mid-range, Vabysmo (₹45,000–65,000) premium. But the per-injection price is misleading: what matters is your Year-1 total (₹60,000–₹2,75,000 depending on drug and how many injections you need). Full tables below. At Crystal Clear Eye Clinic, Andheri West, every patient gets a written annual cost plan before the first injection. Call 077188 85245.

📢 2026 PRICE NEWS most Mumbai websites haven’t updated yet: Bayer cut Eylea (aflibercept 2 mg) prices by ~44% to ₹29,998/vial in April 2026, after India’s first aflibercept biosimilar (Zydus’s Anyra) launched in February 2026. Many aggregator pages still show the old ₹56,000–65,000 Eylea price. Meanwhile Vabysmo (faricimab), launched in India in March 2024 at ~₹67,000–73,000/vial, now trades near ₹50,000–57,000, and Eylea HD (aflibercept 8 mg) is still not launched in India as of July 2026. This page is date-stamped and updated quarterly — that’s why patients trust it.

If your retina specialist has advised anti-VEGF injections for diabetic macular edema, wet AMD, retinal vein occlusion or myopic CNV, the first practical question is always: “Kitna kharcha aayega?” This guide gives you the most transparent answer on the internet — drug-by-drug Mumbai prices, the math aggregators hide, insurance realities, and honest guidance on when a cheaper injection is smart and when it isn’t. For the procedure itself (does it hurt, how it’s done, safety), read our companion guide: intravitreal injection in Andheri West — the complete patient guide.

📋 In this guide:

2026 master price table — every injection drug in Mumbai
The 2026 market shake-up (Eylea price cut, biosimilars, Vabysmo)
Why prices differ so much — and the Avastin secret nobody explains
Cost per letter of vision — the science of value
Year-1 budget math — 3 real patient profiles
Insurance & cashless for injections — the complete playbook
Cheap vs right — when to save and when to step up
The hidden costs nobody counts
Why patients choose Dr. Jignesh Gala
Clinic location, hours & suburbs we serve
FAQs — cost & insurance questions
Research library (180+ verified references)

1. 2026 Master Price Table — Every Anti-VEGF & Retina Injection in Mumbai

Two numbers matter everywhere: the vial MRP (what the drug company charges) and the per-injection procedure price (drug + sterile consumables + specialist’s expertise + same-day checks). Aggregator sites show one number with no date; here is the full picture, verified 22 July 2026:

Drug (molecule)	Vial MRP India (approx)	Per injection at our clinic (₹)	Typical interval	Est. Year-1 total (₹)
Avastin (bevacizumab, off-label)	₹33,863/vial (but yields ~30 eye doses)	₹7,000 – ₹12,000	4–6 weeks	₹55,000 – ₹1,00,000
Biosimilar ranibizumab (Razumab ₹15,937 / Ranieyes ₹19,800 / Ranizurel ₹19,990 MRP)	₹15,900 – ₹20,000/vial	₹8,000 – ₹15,000	4–6 weeks	₹60,000 – ₹1,20,000
Accentrix (ranibizumab, Novartis India)	₹23,960/vial	₹15,000 – ₹28,000	4–6 weeks	₹1,00,000 – ₹2,00,000
Lucentis (ranibizumab, imported)	₹57,000 – ₹70,000/vial	₹18,000 – ₹30,000	4–6 weeks	₹1,30,000 – ₹2,40,000
Eylea (aflibercept 2 mg) — price cut Apr 2026	₹29,998/vial (was ₹53,000+)	₹25,000 – ₹38,000	8–12 weeks	₹1,20,000 – ₹2,00,000
Eylea HD (aflibercept 8 mg)	Not launched in India (expected)	—	12–16 weeks (trial data)	—
Vabysmo (faricimab)	₹67,000 – ₹73,000/vial (market ₹50,000–57,000)	₹45,000 – ₹65,000	12–16 weeks	₹1,50,000 – ₹2,75,000
Pagenax/Beovu (brolucizumab)	₹29,500 – ₹36,670/vial	₹40,000 – ₹60,000	8–12 weeks	₹1,60,000 – ₹2,60,000
Ozurdex (dexamethasone implant)	₹26,000 – ₹30,600	₹25,000 – ₹40,000	3–4 months	₹75,000 – ₹1,20,000

Prices include the injection procedure, sterile consumables and same-day review; they vary with drug batch pricing and your exact protocol. Consultation ₹500–2,000 and OCT scan ₹1,500–3,000 are billed separately on first visit. We hand you this table with YOUR numbers circled before treatment begins.

Dr. Jignesh Gala preparing anti-VEGF injection beside OCT — transparent injection costs at Crystal Clear Eye Clinic Andheri West Mumbai

2. The 2026 Market Shake-Up — Why This Year Changed Everything

Eylea’s 44% price cut (April 2026): Bayer Zydus dropped aflibercept 2 mg from ~₹53,000 to ₹29,998/vial — a direct response to India’s first aflibercept biosimilar, Zydus Anyra (February 2026). If any website still quotes ₹56,000–65,000 for Eylea, their information is stale. Eylea’s trial pedigree (VIEW, VIVID/VISTA, Protocol T) at biosimilar-adjacent pricing makes 2026 the best value year in retina care history.
Biosimilar boom: Razumab (world’s first biosimilar ranibizumab, made by Intas in India), Ranieyes, Ranizurel, Visumab and Oceva have cut monthly-treatment costs by 40–60% with published Indian safety data (Indian J Ophthalmol, 2026 — biosimilar outcomes & cost-effectiveness; Razumab review, 2021).
Vabysmo (faricimab) — launched India March 2024; the dual VEGF+Ang-2 blocker that stretches most patients to 3–4 injections/year (YOSEMITE/RHINE, Lancet 2022). High per-dose price, but the annual math often surprises people (Section 5).
Coming next: Biocon’s Yesafili (aflibercept biosimilar) expected H2 2026; Eylea HD (8 mg) awaits India approval — we update this table the day either launches.

Retina anatomy diagram explaining anti-VEGF injection treatment and costs at Andheri West eye clinic Mumbai

3. Why Do Injection Prices Differ So Much? (And the Avastin Secret Nobody Explains)

Five honest factors drive the price gap:

① The molecule itself

Originator biologics (Lucentis, Eylea, Vabysmo) carry decades of R&D cost; biosimilars reverse-engineer the same molecule after patent expiry at a fraction of the price. Indian cost-effectiveness research measured the raw drug cost per injection at ₹1,648 for bevacizumab vs ₹17,500 for ranibizumab (Clin Ophthalmol, 2021 — Indian DME study).

② The Avastin vial-splitting secret

Here is what no aggregator tells you: one Avastin vial (MRP ~₹33,863) is an oncology vial containing ~30 eye doses. Sterile compounding splits it into single-eye syringes — which is why Avastin is the world’s cheapest anti-VEGF. The Cochrane Collaboration found bevacizumab and ranibizumab equally effective for wet AMD (Cochrane review via Ophthalmology, 2016; CATT trial). Safety depends entirely on sterile splitting technique — at our clinic we use single-use aliquots with OT-grade asepsis, and we tell you openly when Avastin is being used.

③ Procedure & expertise

The per-injection fee covers the retina specialist’s assessment, OCT interpretation, sterile consumables, and post-injection checks — not just the drug. A ₹5,000 injection from a non-retina doctor and a ₹10,000 injection from a vitreoretinal surgeon are not the same product.

④ Dosing interval = hidden multiplier

A ₹10,000 drug needed every month totals ₹1.2 lakh a year; a ₹55,000 drug needed only every 3 months totals ₹2.2 lakh — the gap is far smaller than the 5.5× sticker difference suggests, and if the longer-acting drug also preserves more vision with fewer visits, the value equation can flip entirely. Interval math is everything — hence Section 5.

⑤ GST, storage & cold chain

Biologics need 2–8°C cold-chain storage and carry GST; clinics with proper medical-grade refrigeration (like ours) factor this in. Suspiciously cheap injections often cut exactly this corner.

4. Cost Per Letter of Vision — the Science of “Value”

Health economists measure injections in cost per line of vision gained, not rupees per syringe. What global research shows:

For wet AMD, bevacizumab delivers comparable vision at 10–20× lower drug cost than ranibizumab (Ophthalmology, 2014; IVAN trial, BMJ Open; Br J Ophthalmol modelling)
For diabetic macular edema with poorer starting vision, aflibercept’s extra efficacy can justify its price; a JAMA analysis compared aflibercept-first vs bevacizumab-first strategies (JAMA Ophthalmol, 2023; Protocol T cost analysis)
Faricimab’s durability makes it cost-effective despite the premium price in UK/Japan/China analyses (UK analysis, 2024; Japan analysis, 2025)
Treat-and-extend regimens are formally cost-minimising (Graefe’s Arch, 2022; J Med Econ, 2025)
Even switching to cheaper drugs nationally saves health systems billions (Health Affairs) — and Indian bevacizumab biosimilars show the same pattern (Indian J Pharmacol, 2024)

Our promise: we prescribe the molecule your OCT demands, and the cheapest version of it that doesn’t compromise your outcome. If a ₹10,000 biosimilar will do the job of a ₹55,000 drug, you will hear that from us first.

5. Year-1 Budget Math — 3 Real Patient Profiles

Profile	Drug strategy	Year-1 injections	Year-1 cost (₹)	Best for
Profile A — “Maximum value”	Avastin / biosimilar ranibizumab	8–9	₹70,000 – ₹1,10,000	Budget-first patients, good OCT responders, pensioners
Profile B — “Balanced”	Start biosimilar → step up to Eylea 2mg (post-cut ₹29,998) if response is incomplete	6–7	₹1,10,000 – ₹1,80,000	Most DME patients; 2026’s smartest default after the price cut
Profile C — “Fewest visits”	Vabysmo q12–16 weeks	4–5	₹1,90,000 – ₹2,75,000	Working professionals, outstation patients, poor responders to monthly drugs

Notice: the premium drug costs ~2× the budget one per year — not 6× as the per-injection sticker suggests. For a Bandra or Powai professional who loses a workday per visit, Profile C can actually be the economical choice once travel and leave-days are counted (treatment burden study, 2024; Indian J Ophthalmol, 2026 — invisible costs).

6. Insurance & Cashless for Anti-VEGF Injections — the Complete Playbook

Dr. Jignesh Gala owns and directs two facilities, covering both cashless routes in Mumbai:

🏥 Direct cashless → Topax Eye Care (Topax Eye Hospital), Vile Parle East. Insurers with direct tie-ups approve your injection directly here — walk in with your policy card, we coordinate pre-authorisation (typically 30–60 minutes), and treatment proceeds without upfront payment (per policy terms).

🏥 Third-party cashless (TPA) → Crystal Clear Eye Clinic, Andheri West. TPA-routed claims are processed here — 25–30+ TPAs, GIPSA and public-sector panels handled end-to-end by our insurance desk.

Dr. Jignesh Gala and team at Topax Eye Hospital Vile Parle East — direct cashless anti-VEGF injections Mumbai

The 6 things to check in YOUR policy (we do this free, before your first injection):

Day-care vs OPD: injections claimed as day-care procedures succeed far more often than OPD claims — categorisation is everything
Waiting period: pre-existing diabetes/retinopathy typically carries a 2–4 year wait on individual policies (corporate/group policies often have none)
Per-injection sub-limit: some policies cap per-procedure payout — critical for premium drugs
Annual limit & room-rent linkage: affects multi-injection years
Approved indications: wet AMD, DME and RVO are widely accepted; off-label uses vary
Documents: policy card, photo ID, doctor’s prescription with diagnosis code, OCT report — we prepare the full file

Details: cashless eye treatment in Mumbai · cashless guide by Dr. Gala. No insurance? Ask about EMI plans — spreading ₹1.5L over 12 months beats skipping injections and losing vision.

7. Cheap vs Right — When to Save and When to Step Up

Honest decision framework we use chair-side (and it saves patients lakhs):

Start smart: newly diagnosed DME/RVO with decent vision → Avastin or biosimilar ranibizumab is evidence-backed first-line
Step up on data, not frustration: if OCT shows persistent fluid after 3 loading doses → switch to aflibercept (now far cheaper post-cut) or faricimab — Protocol T proved aflibercept wins in poorer-vision DME (Ophthalmology, 2016)
Choose durability for lifestyle: frequent travellers, working professionals, outstation patients → Vabysmo’s 12–16 week intervals often justify the premium
Steroid implant when inflammation dominates or monthly visits are impossible → Ozurdex, with cost-effectiveness data in naïve DME (2022 analysis; 2023 analysis)
Never skip doses to save money: interrupted treatment loses vision permanently; a cheaper drug taken regularly beats a premium drug taken randomly — Indian real-world data confirms cost-driven dropout is the #1 treatment failure (Indian J Ophthalmol, 2025; RETORT study)

8. The Hidden Costs Nobody Counts

Consultation + OCT: ₹2,000–5,000 per monitoring visit — long-acting drugs need fewer of these too
Workday losses: each monthly visit costs a half-day; ×9 vs ×4 visits is a real salary difference for working patients in Andheri, Bandra, Powai
Travel & attendant: a family member usually accompanies — double the lost hours
Missed-injection relapse: the most expensive “saving” in retina care — restarting after a gap often means re-loading from zero
Both eyes: bilateral disease doubles drug cost; same-day bilateral injections halve the visit burden — ask us

Australian and Indian studies confirm these invisible costs drive real-world outcomes (DME treatment burden study; IJO 2026 — invisible costs of anti-VEGF). Our treat-and-extend planning attacks exactly this.

9. Why Patients Across Mumbai Choose Dr. Jignesh Gala

Dr. Jignesh Gala — retina specialist for affordable anti-VEGF injections in Andheri West Mumbai

Dr. Jignesh Gala — FRCS (Ophth) Glasgow · MRCS Edinburgh · FICO London · DOMS (KEM Hospital) · MBBS (Grant Medical College)

Vitreoretinal & Cataract Surgeon | Founder & Director — Crystal Clear Eye Clinic & Topax Eye Hospital, Mumbai

Retina fellowship, L V Prasad Eye Institute · Former Asst. Professor, B.Y.L. Nair Hospital · Singapore (Tan Tock Seng) experience
BMJ Case Reports peer reviewer — he reads the cost-effectiveness research most doctors skip (inside his BMJ work)
Thousands of injections administered across India & Singapore — every drug from Avastin to Vabysmo
Written annual cost plan before your first injection — no surprise bills, ever

More: best retina specialist in Mumbai · intravitreal injection — procedure guide · eye injection explained simply · DME treatment · ARMD treatment · retina treatment in Andheri · eye specialist profile · retina specialist, Andheri West · vitreoretinal treatment · diabetic retinopathy care · advanced retinal care. More from our clinic: surgical videos, LVPEI fellowship story, retina surgery guide, vitrectomy surgery, sudden floaters check-up, diabetic eye care, understanding diabetic eye disease, macular edema treatment.

Live retina surgery at Topax Eye Hospital operation theatre — anti-VEGF injection facility Mumbai

Dr. Jignesh Gala vitreoretinal surgeon with microscope — honest anti-VEGF injection pricing Mumbai

10. Clinic Location, Hours & Suburbs We Serve

Crystal Clear Eye Clinic — Laram Centre CHS, A1-202, Swami Vivekanand Rd, above Sunil Jewellers, near NADCO Shopping Centre, Railway Colony, Andheri West, Mumbai, Maharashtra 400058 · Open daily, closes 9 pm · Phone/WhatsApp: 077188 85245

Dr. Jignesh Gala at Topax Eye Hospital — affordable anti-VEGF injection clinic near Lokhandwala Versova Andheri West

5–12 minutes from Lokhandwala, Four Bungalows, Seven Bungalows, Versova, Yari Road, DN Nagar, Juhu, JVPD, Vile Parle, Oshiwara, Jogeshwari; 15 min from Goregaon; regular patients from Bandra, Santacruz, Khar, Malad, Kandivali, Powai, Thane, Navi Mumbai and South Mumbai. Our Vile Parle East facility (Topax Eye Care) handles direct-cashless patients.

मराठी सारांश: मुंबईत anti-VEGF डोळ्याच्या इंजेक्शनची किंमत ₹7,000 ते ₹65,000 प्रति डोस आहे — Avastin/biosimilar सर्वात स्वस्त, Vabysmo प्रीमियम. एप्रिल 2026 पासून Eylea ची किंमत 44% ने घटून ₹29,998 झाली आहे. डॉ. जिग्नेश गाला (FRCS) प्रत्येक रुग्णाला वर्षभराचा लेखी खर्च आधीच देतात. कॅशलेस: टोपॅक्स (डायरेक्ट) व क्रिस्टल क्लियर (TPA). फोन: 077188 85245.

हिंदी सारांश: मुंबई में anti-VEGF इंजेक्शन की कीमत ₹7,000–₹65,000 प्रति डोज़ है — Avastin/biosimilar सबसे किफ़ायती, Vabysmo प्रीमियम। अप्रैल 2026 से Eylea की कीमत 44% घटकर ₹29,998 हो गई है। डॉ. जिग्नेश गाला (FRCS) पहले इंजेक्शन से पहले पूरे साल का लिखित बजट देते हैं। कैशलेस: Topax (डायरेक्ट) और Crystal Clear (TPA)। फोन: 077188 85245।

11. FAQs — Anti-VEGF Injection Cost in Mumbai

What is the cheapest anti-VEGF injection available in Mumbai?

Bevacizumab (Avastin) at ₹7,000–12,000 per injection and biosimilar ranibizumab (Razumab/Ranieyes) at ₹8,000–15,000 are the most affordable proven options. Both have strong evidence, and Indian studies confirm biosimilar safety. The “cheapest” choice that’s wrong for your eye is the most expensive mistake — we match drug to disease first, then optimise price.

Why does Vabysmo cost so much more than Avastin?

Vabysmo (faricimab) is a 2022-era dual-pathway biologic (blocks VEGF + Ang-2) with patented technology and ~₹67,000–73,000/vial MRP; Avastin is a repurposed older molecule whose vial splits into ~30 eye doses. But Vabysmo lasts 12–16 weeks vs Avastin’s 4–6 — so annually the gap is ~2×, not 6×.

Has Eylea really become cheaper in 2026?

Yes — Bayer Zydus cut aflibercept 2 mg by ~44% to ₹29,998/vial in April 2026 after India’s first aflibercept biosimilar launched. Websites still quoting ₹56,000–65,000 are outdated. At our clinic Eylea injections now cost ₹25,000–38,000 all-inclusive.

Is the eye injection covered by health insurance in India?

Usually yes for approved indications (wet AMD, DME, RVO) when billed as a day-care procedure. Direct cashless runs through Topax Eye Care (Vile Parle East) and TPA cashless through Crystal Clear Eye Clinic (Andheri West). We verify your policy’s waiting period, sub-limits and categorisation before starting — free.

How much will I spend in the first year of treatment?

Realistic Year-1 budgets: ₹70,000–1,10,000 (Avastin/biosimilar plan), ₹1,10,000–1,80,000 (biosimilar → Eylea step-up), ₹1,90,000–2,75,000 (Vabysmo). Includes 4–9 injections depending on the drug. Your personalised figure is written down at the first visit.

Are biosimilar injections as safe as branded ones?

Yes — Razumab, Ranieyes and other Indian biosimilars have published real-world safety and effectiveness studies (Indian J Ophthalmol 2026, Ophthalmol Ther 2021). India actually pioneered biosimilar ranibizumab globally. We use only CDSCO-approved products with proper cold chain.

Do you offer EMI or payment plans?

Yes — EMI options are available for multi-injection plans, because spreading cost beats skipping doses. Interrupted treatment causes permanent vision loss that no money can buy back. Ask the front desk when planning your Year-1 budget.

Why do different websites show such different prices for the same injection?

Three reasons: stale data (many still show pre-2026 Eylea prices), vial MRP vs all-inclusive procedure price confusion, and templated aggregator pages that show identical prices for every city. Our table is date-stamped, shows both numbers, and is updated quarterly.

Is Avastin safe even though it’s used “off-label”?

Yes — it’s the world’s most-used eye injection with two decades of evidence (CATT trial, Cochrane review) showing effectiveness equal to ranibizumab for wet AMD. Safety depends on sterile compounding; we use single-use aliquots prepared under OT-grade asepsis and always tell you which drug you’re receiving.

Can I switch from an expensive injection to a cheaper one mid-treatment?

Often yes — switching down is common when the retina is dry and stable; switching up is done when response is incomplete. Any switch is OCT-guided and discussed with full cost transparency. Never switch by stopping — gaps cause relapses.

What extra costs should I expect besides the injection?

First visit: consultation (₹500–2,000) + OCT scan (₹1,500–3,000). Monitoring visits need periodic OCTs. Long-acting drugs reduce the number of both injection and monitoring visits — part of their hidden value.

Do government or trust hospitals offer cheaper injections in Mumbai?

Some trust hospitals offer subsidised injections (₹1,500–5,000) with long waiting lists and limited drug choices. For working patients who need specific drugs, evening hours and consistent specialist follow-up, a dedicated retina clinic is usually the practical choice.

Get YOUR Written Cost Plan — Free With Consultation

Crystal Clear Eye Clinic — Laram Centre CHS, A1-202, Swami Vivekanand Rd, above Sunil Jewellers, near NADCO Shopping Centre, Railway Colony, Andheri West, Mumbai 400058 · Open daily, closes 9 pm

📞 Call 077188 85245 💬 WhatsApp for Cost Estimate

Direct cashless via Topax Eye Care · Third-party (TPA) cashless via Crystal Clear Eye Clinic

Disclaimer: Prices are indicative Mumbai ranges verified on 22 July 2026 and change with manufacturer pricing and individual protocols; your written plan after examination is the final word. This page is educational and not a substitute for consultation.

14. Research & Evidence Library — 180+ Verified References

Every price claim and medical statement on this page is backed by verifiable sources — each link checked live on 22 July 2026. Browse by topic:

💰 Cost-Effectiveness & Health Economics Research (33 verified)

🏛️ Global Authorities, Guidelines & Trial Registries (40 verified)

AAO (aao.org) — 7 links

AAO: Anti-VEGF Treatments — Plain-language explainer of what anti-VEGF eye injections are, conditions treated, and what to expect during the shot.
AAO: Diabetic Retinopathy: Causes, Symptoms, Treatment — Patient guide to diabetic eye disease stages, diagnosis (OCT), and treatments including anti-VEGF injections.
AAO: Understanding Macular Degeneration — Patient overview of dry vs wet AMD, AREDS2 vitamins, anti-VEGF therapy, and Amsler grid self-monitoring.
AAO: Retinal Vein Occlusion — Explains BRVO vs CRVO, macular edema, and anti-VEGF/laser treatment options for patients.
AAO: Diabetic Retinopathy PPP 2024 — AAO's official evidence-based clinical guideline for diabetic retinopathy care (free PDF).
AAO: Age-Related Macular Degeneration PPP 2024 (Updated 2026) — AAO's official AMD clinical guideline, including anti-VEGF treatment recommendations.
AAO: Retinal Vein Occlusions PPP 2024 (Updated 2026) — AAO's official RVO clinical guideline covering anti-VEGF agents and aflibercept 8 mg.

EyeWiki (eyewiki.org) — 5 links

EyeWiki: Intravitreal Injections — Physician-reviewed reference on injection technique, indications, and complications.
EyeWiki: Aflibercept — Drug monograph on Eylea: mechanism, dosing, trial evidence.
EyeWiki: Ranibizumab — Drug monograph on Lucentis: mechanism, indications, key trials.
EyeWiki: Faricimab — Drug monograph on Vabysmo, the dual VEGF/Ang-2 inhibitor.
EyeWiki: Endophthalmitis — Reference on the most serious injection complication: signs, management, prognosis.

ASRS (asrs.org) — 5 links

ASRS: Retina Health Series: Intravitreal Injections (fact sheet 30, PDF) — Patient fact sheet on what happens during an eye injection and its risks.
ASRS: Retina Health Series: Age-Related Macular Degeneration (fact sheet 16, PDF) — Patient fact sheet on AMD symptoms, testing, and anti-VEGF treatment regimens.
ASRS: Retina Health Series: Macular Edema (fact sheet 13, PDF) — Patient fact sheet on macular edema causes (incl. diabetes/DME) and treatments.
ASRS: Retina Health Series: Central Retinal Vein Occlusion (fact sheet 21, PDF) — Patient fact sheet on CRVO and its anti-VEGF/laser management.
ASRS: Diabetic Retinopathy (patient disease page) — ASRS patient portal page on diabetic retinopathy symptoms, causes, and treatments.

Retinal Physician (retinalphysician.com) — 3 links

Retinal Physician: Comparing Intravitreal Injection Protocols and Practices (Sept 2010) — Expert roundtable on injection technique nuances: anesthesia, asepsis, needle handling, post-op care.
Retinal Physician: Antisepsis for Intravitreal Injections (April 2023) — How povidone-iodine antisepsis lowers endophthalmitis risk from injections.
Retinal Physician: Endophthalmitis Then and Now (May 2025) — Historical-to-modern review of endophthalmitis prophylaxis and management.

Landmark journal article pages (DOI-resolving) — 6 links

Ophthalmology (AAO journal): Heier JS et al. — Intravitreal Aflibercept (VEGF Trap-Eye) in Wet AMD (VIEW 1/VIEW 2), 2012 — Pivotal trials that established aflibercept 2 mg for wet AMD.
Ophthalmology: Dugel PU et al. — HAWK and HARRIER: Phase 3 Trials of Brolucizumab for nAMD, 2020 — Trials leading to brolucizumab (Beovu) approval.
Lancet: Heier JS et al. — Faricimab in nAMD (TENAYA and LUCERNE), 2022 — Showed faricimab durability up to 16-week intervals in wet AMD.
Lancet: Wykoff CC et al. — Faricimab in DME (YOSEMITE and RHINE), 2022 — Pivotal faricimab trials in diabetic macular edema.
Ophthalmology: CATT Research Group — Ranibizumab and Bevacizumab for nAMD: Two-Year Results, 2012 — Head-to-head comparison of Lucentis vs Avastin for wet AMD.
Ophthalmology: Wells JA et al. (DRCR.net Protocol T) — Aflibercept, Bevacizumab, or Ranibizumab for DME, 2016 — Comparative-effectiveness trial guiding anti-VEGF choice in DME.

ClinicalTrials.gov (all confirmed via official v2 API) — 10 links

ClinicalTrials.gov: YOSEMITE — Faricimab in DME (COMPLETED) — Phase 3 faricimab trial in diabetic macular edema.
ClinicalTrials.gov: RHINE — Faricimab in DME (COMPLETED) — Sister phase 3 faricimab DME trial (official title: "A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema").
ClinicalTrials.gov: PHOTON — Aflibercept 8 mg in DME (COMPLETED) — Phase 3 high-dose aflibercept in diabetic eye disease.
ClinicalTrials.gov: PULSAR — Aflibercept 8 mg in wet AMD (COMPLETED) — Phase 3 high-dose aflibercept in neovascular AMD.
ClinicalTrials.gov: TENAYA — Faricimab in nAMD (COMPLETED) — Phase 3 faricimab in neovascular AMD.
ClinicalTrials.gov: LUCERNE — Faricimab in nAMD (COMPLETED) — Sister phase 3 faricimab nAMD trial.
ClinicalTrials.gov: HAWK — Brolucizumab (RTH258) vs aflibercept, Study 1 (COMPLETED) — Phase 3 brolucizumab trial in wet AMD.
ClinicalTrials.gov: HARRIER — Brolucizumab (RTH258) vs aflibercept, Study 2 (COMPLETED) — Sister phase 3 brolucizumab trial.
ClinicalTrials.gov: Archway — Port Delivery System (Susvimo) with ranibizumab, wet AMD (COMPLETED) — Phase 3 refillable ranibizumab implant vs monthly injections.
ClinicalTrials.gov: VIEW 1 — VEGF Trap-Eye (aflibercept) in wet AMD (COMPLETED) — Pivotal aflibercept wet AMD trial.

NEI (nei.nih.gov) — 2 links

NEI: Age-Related Macular Degeneration — NIH patient resource on AMD types, risk factors, and treatment.
NEI: Diabetic Retinopathy — NIH patient resource on diabetic eye disease and injections/laser/surgery.

MedlinePlus — 2 links

MedlinePlus: Macular Degeneration — Curated NIH patient information hub on AMD.
MedlinePlus: Diabetic Eye Problems — Patient hub on diabetic retinopathy and related eye complications.

📚 Drug-by-Drug Clinical Evidence — PubMed (119 verified)

Ranibizumab For Diabetic Macular Edema

Persistent diabetic macular edema: Definition, incidence, biomarkers, and treatment methods. Survey of ophthalmology, 2023.
Intravitreal Ranibizumab in Diabetic Macular Edema: Long-Term Outcomes. Developments in ophthalmology, 2017.
Ranibizumab in Diabetic Retinopathy with or without Diabetic Macular Edema. Ophthalmology. Retina, 2020.
Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review. International journal of molecular sciences, 2022.
Comparative Efficacy, Durability and Safety of Faricimab in the Treatment of Diabetic Macular Edema: A Systematic Literature Review and Network Meta-Analysis. Advances in therapy, 2023.
Diabetic macular edema. Developments in ophthalmology, 2010.
Systemic safety of ranibizumab for diabetic macular edema: meta-analysis of randomized trials. Retina (Philadelphia, Pa.), 2014.
Race and Vision Outcomes in Ranibizumab-Treated Participants With Diabetic Macular Edema: A Meta-Analysis. JAMA ophthalmology, 2025.
[Recommendations for the use of ranibizumab in diabetic macular edema at IMSS]. Revista medica del Instituto Mexicano del Seguro Social, 2017.
Baseline Diabetic Retinopathy Severity and Time to Diabetic Macular Edema Resolution with Ranibizumab Treatment: A Meta-Analysis. Ophthalmology. Retina, 2023.

Aflibercept For Diabetic Macular Edema

Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials. Ophthalmology, 2024.
IMPACT OF FARICIMAB VERSUS AFLIBERCEPT ON EPIRETINAL MEMBRANE FORMATION OVER 2 YEARS IN PATIENTS WITH DIABETIC MACULAR EDEMA IN THE PHASE 3 YOSEMITE AND RHINE TRIALS. Retina (Philadelphia, Pa.), 2025.
Aflibercept versus ranibizumab for diabetic macular edema: A meta-analysis. European journal of ophthalmology, 2024.
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology, 2016.
Clinical trials and real-world studies examining faricimab and high-dose aflibercept for wet age-related macular degeneration and diabetic macular edema. Current opinion in ophthalmology, 2025.
Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON Trial. Ophthalmology, 2026.
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial. Lancet (London, England), 2024.
Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema. The New England journal of medicine, 2022.
Anatomic Control with Faricimab versus Aflibercept in the YOSEMITE/RHINE Trials in Diabetic Macular Edema. Ophthalmology. Retina, 2025.
Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study). Ophthalmology, 2020.

Faricimab (Vabysmo) Trials

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet (London, England), 2022.
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2. Ophthalmology, 2024.
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet (London, England), 2022.
Four-Year Outcomes of Faricimab in Diabetic Macular Edema: Results from the RHONE-X Extension Trial. Ophthalmology, 2026.
Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. Ophthalmology, 2019.
Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO Trials. Ophthalmology, 2024.
Anatomic Outcomes with Faricimab vs Aflibercept in Head-to-Head Dosing Phase of the TENAYA/LUCERNE Trials in Neovascular Age-related Macular Degeneration. Ophthalmology, 2025.
Faricimab Treat-and-Extend Dosing for Macular Edema Due to Retinal Vein Occlusion: 72-Week Results from the BALATON and COMINO Trials. Ophthalmology. Retina, 2025.
Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2024.

Aflibercept 8 Mg (Photon / Pulsar)

Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials. Ophthalmology and therapy, 2025.
A Matching-Adjusted Comparison of Faricimab and Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema. Ophthalmic research, 2026.
Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US. Ophthalmology and therapy, 2025.
Intraocular Pressure Outcomes with Intravitreal Aflibercept 8 mg: A 96-Week Pooled Analysis from PULSAR and PHOTON. Ophthalmology and therapy, 2026.
A Response to: Letter to the Editor Regarding "Aflibercept 8 mg Versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials". Ophthalmology and therapy, 2026.
Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial. JAMA ophthalmology, 2023.
High-Dose 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration: Who Is Being Treated with This New Agent? Life (Basel, Switzerland), 2025.
Aflibercept high-dose (8mg) related intraocular inflammation (IOI) – a case series. BMC ophthalmology, 2024.
Clinical Outcomes of High-Dose Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: A Systematic Review and Meta-Analysis. Cureus, 2026.
Initial Functional and Anatomical Outcomes of High-dose Aflibercept 8 mg in Exudative Neovascular Age-related Macular Degeneration. Ophthalmology. Retina, 2025.

Brolucizumab

Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER. Ophthalmology, 2021.
Understanding Retinal Vasculitis Associated with Brolucizumab: Complex Pathophysiology or Occam's Razor? Ocular immunology and inflammation, 2022.
[Efficacy of brolucizumab in the treatment of retinal pathologies: a review of post-marketing studies]. Vestnik oftalmologii, 2024.
RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Review of Real-World Evidence. Retina (Philadelphia, Pa.), 2023.
EXUDATIVE RETINAL DETACHMENT AFTER INTRAVITREAL BROLUCIZUMAB INJECTION. Retinal cases & brief reports, 2023.
Retinal vasculitis after intravitreal injection of brolucizumab. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 2022.
Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab. Ophthalmology, 2020.
Brolucizumab-associated intraocular inflammation in eyes without retinal vasculitis. Journal of vitreoretinal diseases, 2021.
Occlusive Retinal Vasculitis Following Intravitreal Brolucizumab. Journal of vitreoretinal diseases, 2020.
KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema. American journal of ophthalmology, 2022.

Ranibizumab Biosimilars

Approved biosimilar ranibizumab-a global update. Eye (London, England), 2023.
Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation. Ophthalmology and therapy, 2022.
Biosimilar ranibizumab interchangeability: what does it mean to retinal physicians? Eye (London, England), 2023.
Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study. Journal of vitreoretinal diseases, 2025.
Biosimilar ranibizumab (BS1) – early experience from Japan (BRIJ study). Eye (London, England), 2024.
Treatment Landscape of Macular Disorders in Indian Patients with the Advent of Razumab™ (World's First Biosimilar Ranibizumab): A Comprehensive Review. Ophthalmology and therapy, 2021.
Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs. Eye (London, England), 2024.
Innovator Versus Biosimilar Ranibizumab in Polypoidal Choroidal Vasculopathy: Real-World Evidence. Ophthalmology and therapy, 2022.
FYB-201 Biosimilar ranibizumab (Ongavia/Ranivisio/Cimerli) Efficacy and Safety in Clinical Settings – FORCE study. Eye (London, England), 2025.
Biosimilar Ranibizumab and Innovator Ranibizumab-Immunogenicity Assessment and Its Impact on Safety and Efficacy. JAMA ophthalmology, 2023.

Anti-Vegf For Neovascular Amd

VEGF in Diabetic Retinopathy and Age-Related Macular Degeneration. International journal of molecular sciences, 2025.
Fibrosis in age-related neovascular macular degeneration in the anti-VEGF era. Eye (London, England), 2024.
Targeting C3b/C4b and VEGF with a bispecific fusion protein optimized for neovascular age-related macular degeneration therapy. Science translational medicine, 2022.
Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities. Progress in retinal and eye research, 2021.
[Anti-VEGF therapy resistance in neovascular age-related macular degeneration]. Vestnik oftalmologii, 2017.
Exploring new horizons in neovascular age-related macular degeneration: novel mechanisms of action and future therapeutic avenues. Eye (London, England), 2025.
Anti-angiogenic biomolecules in neovascular age-related macular degeneration; therapeutics and drug delivery systems. International journal of pharmaceutics, 2024.
Treatment Strategies for Anti-VEGF Resistance in Neovascular Age-Related Macular Degeneration by Targeting Arteriolar Choroidal Neovascularization. Biomolecules, 2024.
Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). The British journal of ophthalmology, 2014.
Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug design, development and therapy, 2016.

Retinal Vein Occlusion Anti-Vegf

Integrated Assessment of OCT, Multimodal Imaging, and Cytokine Markers for Predicting Treatment Responses in Retinal Vein Occlusion Associated Macular Edema: A Comparative Review of Anti-VEGF and Steroid Therapies. Diagnostics (Basel, Switzerland), 2024.
[Retinal vein occlusion: anti-VEGF treatments]. Journal francais d'ophtalmologie, 2009.
Retinal Vein Occlusion. Developments in ophthalmology, 2016.
Use of Anti-VEGF Drugs in Retinal Vein Occlusions. Current drug targets, 2020.
Effectiveness and safety of anti-vascular endothelial growth factor therapies for macular edema in retinal vein occlusion: A systematic review and network meta-analysis of randomized controlled trials. Survey of ophthalmology, 2025.
Real-World Visual and Neovascularisation Outcomes from anti-VEGF in Central Retinal Vein Occlusion. Ophthalmic epidemiology, 2021.
Retinal vein occlusion. Handbook of clinical neurology, 2026.
Efficacy and Safety of Intravitreal Faricimab in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion: A Meta-Analysis. Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 2024.
[Long-term outcomes of anti-VEGF therapy for macular edema in retinal vein occlusion]. Vestnik oftalmologii, 2022.
Photocoagulation for retinal vein occlusion. Progress in retinal and eye research, 2021.

Dexamethasone Implant (Ozurdex)

Reverse engineering the Ozurdex dexamethasone intravitreal implant. International journal of pharmaceutics, 2023.
Dexamethasone intravitreal implant (OZURDEX(®)) for macular edema secondary to noninfectious uveitis: a review of the literature. Therapeutic delivery, 2019.
OZURDEX® (Dexamethasone Intravitreal Implant) 0.7 mg as Initial Therapy in Pseudophakic Patients With Diabetic Macular Edema, Macular Edema Following Retinal Vein Occlusion, and Noninfectious Posterior Segment Uveitis: A Case-Based Discussion. Retina (Philadelphia, Pa.), 2019.
Intraoperative Dexamethasone Intravitreal Implant (Ozurdex) in Vitrectomy Surgery for Epiretinal Membrane. Current eye research, 2020.
CASE REPORT OF ABIOTROPHIA DEFECTIVA ENDOPHTHALMITIS AFTER REPEATED INJECTIONS OF DEXAMETHASONE INTRAVITREAL IMPLANT (OZURDEX). Retinal cases & brief reports, 2022.
PERSISTENT REMNANTS OF DEXAMETHASONE INTRAVITREAL IMPLANT (OZURDEX). Retina (Philadelphia, Pa.), 2020.
Dexamethasone intravitreal implant (Ozurdex) for the treatment of pediatric uveitis. Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus, 2014.
Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex®) in its treatment. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2016.
Spontaneous extrusion of a dexamethasone intravitreal implant (Ozurdex). BMJ case reports, 2020.
Protracted Intralenticular Implant of Sustained-Release Dexamethasone Implant (Ozurdex). Klinische Monatsblatter fur Augenheilkunde, 2024.

Treat-And-Extend Anti-Vegf

Treat-and-extend dosing of intravitreal anti-VEGF agents in neovascular age-related macular degeneration: a meta-analysis. Eye (London, England), 2023.
TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations. Retina (Philadelphia, Pa.), 2015.
Vitrectomy as an Adjunct to Treat-and-Extend Anti-VEGF Injections for Diabetic Macular Edema: The Vitrectomy in Diabetic Macular Oedema (VIDEO) Randomized Clinical Trial. JAMA ophthalmology, 2024.
Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis. Eye (London, England), 2023.
Treat and Extend Treatment Interval Patterns with Anti-VEGF Therapy in nAMD Patients. Vision (Basel, Switzerland), 2019.
A Systematic Review of the Treat and Extend Treatment Regimen with Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration. Ophthalmology and therapy, 2017.
The Role of Intravitreal Corticosteroids in the Treatment of DME: Predictive OCT Biomarkers. International journal of molecular sciences, 2022.
Progress and Challenges of Anti-VEGF Agents and Their Sustained-Release Strategies for Retinal Angiogenesis. Drug design, development and therapy, 2022.
Treat and Extend Anti-VEGF Treatment Regimens for Neovascular Age-Related Macular Degeneration: To Stop or Not to Stop? Clinical & experimental ophthalmology, 2025.
Treat-and-extend regimens of anti-vascular endothelial growth factor therapy for retinal vein occlusions: a systematic review and meta-analysis. Acta ophthalmologica, 2022.

Intravitreal Injection Real-World India

Real-World Evidence in the Management of Diabetic Macular Edema with Intravitreal Anti-VEGFs in Asia: A Systematic Literature Review. Clinical ophthalmology (Auckland, N.Z.), 2022.
Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases. Ophthalmology and therapy, 2021.
REal-world treatment outcomes after delayed intRavitreal therapy in center-involving diabetic macular edema – RETORT study. International journal of retina and vitreous, 2023.
"Real world outcomes of intravitreal brolucizumab for persistent diabetic macular edema". International journal of retina and vitreous, 2025.
Real-world experience of brolucizumab in nAMD. Indian journal of ophthalmology, 2024.
Real-world outcomes of intravitreal anti-vascular endothelial growth factor monotherapy in proliferative type 2 macular telangiectasia. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2021.
Ranizurel safety evaluation in real-world -(RaSER) study. American journal of ophthalmology case reports, 2022.
Initial experience with brolucizumab for neovascular age-related macular degeneration (nAMD) in India – Multicentric, real-world study. Indian journal of ophthalmology, 2024.
Real-world evidence of safety profile of intravitreal bevacizumab (Avastin) in an Indian scenario. Indian journal of ophthalmology, 2017.
Factors determining compliance with recommended intravitreal injections for retinal diseases among out-of-pocket, fully subsidized (non-paying), and insured patients: Real-world evidence from India. Indian journal of ophthalmology, 2025.

drjigneshgala@gmail.com

See Full Bio